The journey of canakinumab; on- and off-label indications

  • Daniela Marotto Rheumatology Unit, P. Dettori Hospital, Tempio Pausania (SS), Italy.
  • Alberto Batticciotto Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale di Circolo - Fondazione Macchi, Varese, Italy.
  • Angela Ceribelli Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.
  • Piercarlo Sarzi Puttini | piercarlo.sarziputtini@gmail.com Rheumatology Unit, ASST Fatebenefratelli-Sacco, Milano, Italy.

Abstract

The role of interleukin-1 (IL-1) has been studied in many diseases, ranging from auto-inflammatory diseases to malignancies, and much has been discovered. There are currently four IL-1 inhibitors available, but only two have been approved in Europe: the receptor antagonist anakinra, and the IL-1b selective inhibitor canakinumab. The aim of this paper is to summarise the on- and off-label use of canakinumab (ILARIS®).

Downloads

Download data is not yet available.
Published
2019-05-06
Section
Reviews
Keywords:
IL-1β, inflammation, interleukin 1, rheumatic disease, IL-1 inhibitors, auto-inflammatory disease, CAPS, TRAPS, biological therapies, familial Mediterranean fever, adult-onset Still disease, SJIA, HIDS, pregnancy.
Statistics
Abstract views: 83

PDF: 94
HTML: 1
Share it
How to Cite
Marotto, D., Batticciotto, A., Ceribelli, A., & Sarzi Puttini, P. (2019). The journey of canakinumab; on- and off-label indications. Beyond Rheumatology, 1(1), 22-30. https://doi.org/10.4081/br.2019.4

Most read articles by the same author(s)